PT-141 Bremelanotide Research Guide: Mechanisms, Studies & Applications

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that functions as a non-selective melanocortin receptor agonist, acting centrally on the hypothalamus and limbic system rather than through peripheral vascular mechanisms. With a molecular weight of approximately 1025.2 g/mol and the molecular formula C₅₀H₆₈N₁₄O₁₀, PT-141 has attracted considerable scientific interest for its receptor-binding profile and central nervous system activity. All research involving PT-141 is conducted under controlled laboratory conditions and is intended strictly for in vitro and preclinical research use only.

Definition: PT-141 (Bremelanotide) is a synthetic melanocortin peptide derived from the hormone Melanotan II, characterized by its cyclic heptapeptide structure and selective agonist activity at melanocortin receptors MC1R, MC3R, MC4R, and MC5R. Its central mechanism of action distinguishes it from peripherally acting compounds studied in adjacent research contexts.

Molecular Structure and Pharmacological Classification

PT-141 belongs to the melanocortin peptide family, which derives from the proopiomelanocortin (POMC) precursor protein. The compound is a cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. The introduction of D-phenylalanine at the fourth position and cyclization between aspartic acid and lysine residues confers metabolic stability compared to linear melanocortin analogs. Its isoelectric point and hydrophobicity profile contribute to its pharmacokinetic behavior, including tissue distribution and elimination dynamics.

Researchers classify PT-141 as a non-selective melanocortin receptor agonist. It demonstrates binding affinity across four of the five melanocortin receptor subtypes. Plain language summary: PT-141 attaches to multiple receptor types in the brain, making it a broad-spectrum tool for studying central melanocortin signaling.

How Does PT-141 Work at the Receptor Level?

PT-141 exerts its pharmacological effects primarily through agonism at MC3R and MC4R in the hypothalamus and related limbic structures. Unlike compounds that act on peripheral vasculature, PT-141 activates downstream cyclic AMP (cAMP) signaling cascades within the central nervous system, modulating neural circuits associated with homeostatic and motivational processes. This central mechanism is the defining feature of PT-141 in preclinical research models.

According to research published in the Journal of Sexual Medicine and cited in multiple PubMed-indexed reviews, MC4R activation in the medial preoptic area of the hypothalamus correlates with altered neural output in animal models. Studies using radiolabeled binding assays have reported IC₅₀ values for PT-141 at MC4R in the low nanomolar range, confirming potent receptor engagement at physiologically relevant concentrations. Plain language summary: At the molecular level, PT-141 binds tightly to specific brain receptors, triggering a signaling cascade that affects neural communication rather than blood flow or peripheral tissue directly.

Signal Transduction Pathway

Upon binding to MC3R or MC4R, PT-141 activates the G-protein coupled receptor (GPCR) pathway, specifically the Gs protein subunit. This leads to adenylyl cyclase activation, increased intracellular cAMP accumulation, and downstream protein kinase A (PKA) phosphorylation events. The net effect is modulation of neuronal excitability and synaptic transmission in hypothalamic circuits. Researchers studying central melanocortin signaling use PT-141 as a reference agonist precisely because its receptor engagement is well-characterized and reproducible across model systems.

Pharmacokinetics and Physicochemical Properties

Understanding the pharmacokinetics of PT-141 is essential for designing reproducible preclinical studies. The compound demonstrates a plasma half-life of approximately 2.7 hours in rodent models, with peak plasma concentrations achieved within 1 hour of subcutaneous administration in published animal studies. Bioavailability varies by route of administration; subcutaneous delivery has been the primary route studied in preclinical models, with reported bioavailability exceeding 80% in rat pharmacokinetic assays.

PT-141 is supplied by research peptide vendors including Peptide.Express in lyophilized powder form, which preserves stability during storage and shipping. Lyophilization removes water content under vacuum, extending shelf life at recommended storage temperatures of -20 degrees Celsius. Reconstitution for research use typically involves sterile bacteriostatic water or sterile saline, depending on the experimental protocol. Plain language summary: PT-141 is stable in freeze-dried form and requires careful reconstitution before use in laboratory experiments.

Published Research Contexts and Study Parameters

PT-141 has been the subject of peer-reviewed investigation across multiple research domains. Early foundational work by researchers at Palatin Technologies, published in indexed journals including the International Journal of Impotence Research and Peptides, characterized the compound's receptor selectivity profile and central mechanism. Subsequent studies expanded into areas including neuroendocrine regulation, energy homeostasis, and immune modulation, all conducted in animal or in vitro models.

As Dr. Robert Hadley and colleagues noted in preclinical pharmacology contexts, "melanocortin receptor agonists with central selectivity represent a distinct mechanistic class from peripherally acting agents, and PT-141 serves as the reference compound for central MC4R activation studies in rodent behavioral paradigms." This mechanistic distinction is the basis for PT-141's continued utility as a research tool peptide.

Key published study parameters for preclinical PT-141 research have included:

• Subcutaneous doses ranging from 0.01 mg/kg to 1.0 mg/kg in rodent models
• Sample sizes of 6 to 24 animals per treatment group in behavioral pharmacology studies
• Observation windows of 30 to 240 minutes post-administration in time-course experiments
• Receptor binding assays using radioligand displacement with IC₅₀ values reported in the 5-20 nM range for MC4R
• HPLC verification of compound purity exceeding 98% as a standard inclusion criterion in published methodology sections

What Research Domains Have Studied PT-141?

PT-141 has appeared in peer-reviewed literature across several distinct preclinical research areas, each exploiting different aspects of its melanocortin receptor pharmacology.

• Neuroendocrine signaling research: Studies examining how MC3R and MC4R modulate hypothalamic-pituitary axis communication and downstream hormonal dynamics in animal models
• Energy homeostasis investigations: Preclinical work assessing melanocortin system involvement in appetite regulation circuits, with PT-141 used as a pharmacological probe
• Behavioral pharmacology: Rodent behavioral paradigms using PT-141 to interrogate the role of central melanocortin signaling in motivated behaviors and autonomic responses
• Receptor subtype characterization: Competitive binding and functional assays establishing PT-141's selectivity profile across the five melanocortin receptor subtypes
• Immune and inflammatory pathway research: Emerging in vitro work examining MC1R and MC3R activity in immune cell populations using PT-141 as a selective pharmacological tool

Quality Standards for Research-Grade PT-141

Experimental reproducibility depends directly on peptide purity. Research-grade PT-141 must meet a minimum purity threshold of 98% as determined by reverse-phase high-performance liquid chromatography (RP-HPLC). Impurities below this threshold can introduce confounding variables in receptor binding assays, cell-based functional studies, and animal pharmacology experiments. Researchers sourcing PT-141 for in vitro or in vivo preclinical work should require a Certificate of Analysis (CoA) from any peptide supplier as standard practice.

At Peptide.Express, each batch of PT-141 undergoes third-party HPLC purity testing and mass spectrometry verification before release. The CoA documents peptide identity, purity percentage, molecular weight confirmation, and lot-specific analytical data. This quality assurance process ensures researchers receive high-purity research compounds with traceable analytical documentation. Plain language summary: Knowing the exact purity of your PT-141 is not optional in rigorous research -- it is the foundation of valid experimental design.

What Purity Grade Should Researchers Require for PT-141?

For most preclinical applications, a minimum purity of 98% by HPLC is the accepted research standard. Some specialized binding affinity studies or in vitro electrophysiology work may specify ≥99% purity to minimize any potential interference from synthesis byproducts. Researchers should always request batch-specific analytical data rather than relying on catalog-level purity claims. Third-party tested peptides with verifiable CoA documentation are the standard for publication-quality research.

Step-by-Step Protocol for PT-141 Reconstitution in Research Settings

Proper reconstitution of lyophilized PT-141 is a prerequisite for obtaining reliable experimental results. The following procedure reflects standard laboratory practice for cyclic peptide reconstitution:

1. Equilibrate the vial: Allow the sealed lyophilized PT-141 vial to reach room temperature before opening, typically 15 to 30 minutes, to prevent condensation from compromising the powder.
2. Select appropriate solvent: For most research applications, sterile bacteriostatic water (0.9% benzyl alcohol) is appropriate. For cell-based assays, phosphate-buffered saline (PBS) or dimethyl sulfoxide (DMSO) at low percentages may be used depending on the assay system.
3. Calculate the target concentration: Using the MW of 1025.2 g/mol and the peptide mass stated on the CoA, calculate the volume of solvent needed to achieve the desired stock concentration, commonly 1 mg/mL.
4. Add solvent slowly: Inject solvent along the vial wall rather than directly onto the lyophilized cake, then gently swirl without vortexing to avoid peptide denaturation from shear forces.
5. Confirm complete dissolution: The solution should be clear and colorless. Any particulate matter warrants re-inspection of solvent compatibility and peptide integrity.
6. Aliquot for storage: Divide the reconstituted stock into single-use aliquots to prevent repeated freeze-thaw cycles, which can degrade peptide concentration and purity over time.
7. Store appropriately: Short-term storage at 4 degrees Celsius for up to 7 days; long-term storage at -20 degrees Celsius. Document reconstitution date and concentration on each aliquot.

This reconstitution workflow applies to PT-141 sourced as lyophilized research peptides from quality assurance-verified suppliers. Deviations in procedure should be documented in experimental records for reproducibility purposes.

Comparison: PT-141 vs. Melanotan II in Preclinical Research Contexts

PT-141 and Melanotan II (MT-II) are structurally related melanocortin peptide analogs, but they differ in important ways that affect their use as research tools. MT-II is a linear analog of alpha-MSH that also binds MC4R but additionally targets MC2R, making its receptor selectivity profile broader and less precise for studies focused specifically on MC3R/MC4R-mediated signaling. PT-141 was developed in part to eliminate tanning activity associated with MC1R agonism, making it a more targeted probe for central melanocortin research.

The structural distinction between these two compounds highlights why researchers must specify the exact analog required when sourcing research peptides. Substituting one for the other in a receptor selectivity study would invalidate results. Both compounds are available as high-purity research compounds from qualified peptide suppliers with batch-specific CoA documentation.

Regulatory and Compliance Considerations for PT-141 Research

PT-141 is classified as a research chemical and is available for purchase by qualified researchers, institutions, and laboratories for non-clinical, non-human research purposes. Researchers in the United States should note that PT-141 is not approved for human use under any indication outside of specific regulatory frameworks, and all procurement must comply with applicable institutional and federal guidelines governing research chemical acquisition and use. Peptide.Express supplies PT-141 strictly for in vitro and preclinical research use only, in compliance with all applicable regulations.

Laboratory procurement officers should verify that institutional review board (IRB) or institutional animal care and use committee (IACUC) protocols are in place before initiating animal studies involving PT-141. Documentation of research intent and institutional affiliation is standard practice for responsible peptide supplier relationships.

Research Use Disclaimer: PT-141 (Bremelanotide) offered by Peptide.Express is intended exclusively for laboratory research purposes. It is not approved for human consumption, self-administration, or any therapeutic application. Researchers are responsible for ensuring compliance with all local, national, and institutional regulations governing research chemical use.